ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC | VuMedi

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

10 seconds

Playback speed

ASCO 2022 Conference Coverage

ASCO 2022 on an Open-Label, Multicenter, Randomized Phase II Study of Atezolizumab & Bevacizumab With Y90 TARE in Unresectable HCC

By ASCO 2022 Conference Coverage FEATURING Aiwu Ruth He, Filip Banovac

By ASCO 2022 Conference Coverage FEATURING Aiwu Ruth He, Filip Banovac

241 views

June 23, 2022

Comments 0

Login to view comments. Click here to Login